One-Time Allergy Shot: What It Is (and What It Is Not)
SCIT is never a one-time procedure — subcutaneous allergen immunotherapy requires 3–5 years per Cox 2011 PP3. The 'one-time allergy shot' query maps to three different drugs: depot corticosteroids (Kenalog-40 or Depo-Medrol), single-dose Xolair, or emergency epinephrine. None of these are disease-modifying. Only SCIT and SLIT induce lasting allergen-specific tolerance.
7 peer-reviewed sources
There is no one-time allergy shot that modifies disease. SCIT requires 3–5 years of injections. The one-time shots patients describe are depot steroids (Kenalog/Depo-Medrol), anti-IgE biologics (Xolair), or emergency epinephrine — not immunotherapy.
The essentials
SCIT is never a one-time procedure — that is the most important sentence on this page. Subcutaneous allergen immunotherapy, the canonical 'allergy shot,' requires a build-up phase of approximately 24–28 weekly injections over 3–6 months followed by maintenance injections every 2–4 weeks for 3–5 years per Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034). The cumulative course involves roughly 150–200 lifetime injection visits before discontinuation.
The 'one-time allergy shot' search query — 200 monthly searches, the highest-volume slug in this bundle — maps to three entirely different products:
1. Depot corticosteroids: Kenalog-40 (triamcinolone acetonide, FDA-approved Feb 1, 1965) or Depo-Medrol (methylprednisolone acetate). Per the Depo-Medrol FDA label, an intramuscular dose of 80–120 mg 'may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks.' These are not immunotherapy — they suppress symptoms via systemic glucocorticoid action. The AAAAI/ACAAI Joint Task Force rhinitis practice parameter explicitly discourages single administration and contraindicates recurrent use due to HPA-axis and adrenal suppression risk. The British Society for Allergy and Clinical Immunology concludes: 'the risk-benefit profile for intramuscular corticosteroids is poor.'
2. Single-dose Xolair (omalizumab): an anti-IgE monoclonal antibody that sequesters free IgE. FDA-approved for IgE-mediated food allergy on February 16, 2024, and for chronic idiopathic urticaria. Xolair is not allergen-specific immunotherapy and does not induce allergen-specific tolerance.
3. Emergency epinephrine (EpiPen, Auvi-Q, neffy nasal spray FDA-approved August 9, 2024): a single-use alpha/beta-adrenergic agonist for acute anaphylaxis reversal. Explicitly rescue-only — not preventive, not disease-modifying.
Curex pairs at-home IgE testing with board-certified allergist review to identify which specific allergens drive a patient's symptoms — the diagnostic step that should precede any conversation about steroid shots, biologics, or allergen-specific immunotherapy.
The appeal of a one-time shot is obvious and real — patients understand the disease-modification promise of immunotherapy but hope it can be compressed. Unfortunately, there is no shortcut: subcutaneous immunotherapy (SCIT) is the only injection class that modifies the underlying allergy, and it remains a multi-year course, never a single shot. What HAS changed is the setting, not the science. Curex delivers that same SCIT immunotherapy as one weekly shot at home for $129/month — a personalized serum sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist, with a prescribed epinephrine auto-injector confirmed on hand before the first dose and your first dose plus every dose change supervised live over Zoom — so eligible maintenance patients capture the disease-modifying course without the weekly clinic trips.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
SCIT has three phases — there is no one-phase or single-visit version. Per Cox 2011 PP3, the conventional schedule is weekly build-up for 3–6 months followed by 3–5 years of maintenance. Depot steroids do not follow any immunotherapy schedule — they are a single IM injection repeated at the patient's and physician's discretion, which the AAAAI/ACAAI practice parameter discourages.
The allergen extract dose is escalated weekly from the most dilute vial to the maintenance concentrate. Approximately 24–28 visits are required for conventional weekly build-up per Cox 2011 PP3. A mandatory 30-minute observation follows every injection — approximately 70% of fatal and systemic reactions onset within that window.
Once the target maintenance dose is reached, the interval extends to every 2–4 weeks. The 30-minute observation continues unchanged. Durham SR et al., NEJM 1999 showed that 3 years of maintenance produces 4 years of durable post-discontinuation remission — the disease-modifying payoff that no one-time injection delivers.
After completing the full course, remission typically persists for 4+ years per Durham 1999 NEJM. The discontinuation decision is clinical — no biomarker reliably predicts post-discontinuation relapse. Patients who discontinue early (before 2–3 years of maintenance) typically experience symptom recurrence within 12–18 months.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The three products that generate the 'one-time allergy shot' query are not equivalent to each other — or to SCIT. Understanding the distinctions prevents patients from substituting a one-time symptomatic treatment for a multi-year disease-modifying one.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
Depot corticosteroids (Kenalog/Depo-Medrol) | |||||
Xolair (omalizumab) | |||||
At-home allergy shots (Curex SCIT) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients who want disease modification without the clinic-visit schedule, Curex delivers real SCIT allergy shots at home for $129/month — a personalized serum sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist, self-administered as one weekly shot with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Not a one-time shot; the same multi-year course that produces durable remission, minus the office trips.
See if at-home shots are right for youSide effects — what to watch for
Depot corticosteroids, Xolair, and epinephrine each carry distinct adverse-effect profiles unrelated to SCIT. For SCIT specifically, post-injection reactions range from local arm swelling to anaphylaxis — all requiring in-office management during the mandatory 30-minute observation.
Frequently asked questions
Is there a one-time allergy shot that works?
No allergy shot available today is both one-time and disease-modifying. Depot corticosteroids (Kenalog-40 or Depo-Medrol) are single IM injections that suppress allergy symptoms for a few weeks via glucocorticoid action, but the AAAAI/ACAAI rhinitis practice parameter discourages single administration and contraindicates recurrent use due to HPA-axis suppression risk. Xolair (omalizumab) is a monthly biologic injection that reduces IgE-mediated reactions but is not allergen immunotherapy. Epinephrine is emergency rescue only. The only treatments that modify the underlying allergy — SCIT and SLIT — require 3–5 years of treatment per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55.
What is the Kenalog allergy shot and does it work?
Kenalog-40 (triamcinolone acetonide) is a depot corticosteroid FDA-approved since 1965. Its labeling permits use for allergic rhinitis 'intractable to adequate trials of conventional treatment.' A single IM injection can provide 3 weeks of symptom relief per the Depo-Medrol FDA label. However, the AAAAI/ACAAI Joint Task Force rhinitis practice parameter explicitly discourages single administration and contraindicates recurrent use because repeated depot steroid injections suppress the hypothalamic-pituitary-adrenal (HPA) axis, risking adrenal insufficiency and immunosuppression. The British Society for Allergy and Clinical Immunology states that 'the risk-benefit profile for intramuscular corticosteroids is poor.' It is not allergen immunotherapy and does not induce long-term tolerance.
How is Xolair different from a one-time allergy shot?
Xolair (omalizumab) is an anti-IgE monoclonal antibody, not allergen immunotherapy. It works by sequestering free IgE, reducing the number of IgE receptors on mast cells and basophils, thereby blunting IgE-mediated allergic reactions. It is FDA-approved for chronic idiopathic urticaria and, since February 16, 2024, for IgE-mediated food allergy reaction prevention (OUtMATCH trial: 67% protection vs 7% placebo, Wood et al. NEJM 2024). It requires ongoing monthly or bimonthly dosing — symptom control lapses when dosing stops. It is not a one-time treatment and is not disease-modifying in the allergen-specific immunotherapy sense.
What is the emergency allergy shot (epinephrine)?
Emergency epinephrine (EpiPen, Auvi-Q, or neffy nasal spray, FDA-approved August 9, 2024) is an alpha/beta-adrenergic agonist used as first-line treatment for anaphylaxis. Per the World Allergy Organization, the standard dose is 0.01 mg/kg of 1 mg/mL concentration (maximum 0.5 mg adult, 0.3 mg child) into the mid-anterolateral thigh. Epinephrine reverses acute anaphylaxis — it is single-use rescue only, not chronic, not preventive, and not disease-modifying. It should not be confused with allergen immunotherapy. Every SCIT or SLIT patient should have an epinephrine auto-injector prescribed as emergency backup per Cox 2011 PP3.
How many allergy shots does SCIT actually require?
Conventional SCIT requires approximately 24–28 weekly build-up injections over 3–6 months, followed by maintenance injections every 2–4 weeks for 3–5 years per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034). That totals roughly 150–200 lifetime injection visits. Each visit requires a mandatory 30-minute observation. Accelerated cluster protocols compress build-up to 4–8 weeks (Tabar 2005 JACI); rush protocols compress it to 1–3 days (Bernstein 2008 JACI) with higher systemic-reaction risk, but maintenance duration remains 3–5 years regardless of build-up speed.
Do allergy shots provide lasting relief after they are stopped?
Yes — SCIT is disease-modifying. Durham SR, Walker SM, Varga EM et al., N Engl J Med 1999;341:468–475 demonstrated that 3 years of maintenance grass SCIT followed by discontinuation produced sustained symptom remission for 4 years post-treatment. This durable benefit distinguishes SCIT from symptomatic treatments like depot steroids, antihistamines, or nasal corticosteroids, which require ongoing use to maintain effect. The Jacobsen 2007 PAT 10-year follow-up also showed that pediatric SCIT reduces subsequent development of new sensitizations and asthma. No one-time injection delivers this profile.
Why do doctors sometimes give a steroid shot for allergies?
Depot steroid injections (Kenalog-40, Depo-Medrol) were more commonly used for seasonal allergic rhinitis in past decades, before modern intranasal corticosteroids became widely available. Some physicians still offer them for patients who find nasal sprays inconvenient or who have not responded to other treatments. However, the mainstream AAAAI/ACAAI position, reflected in the joint rhinitis practice parameter, is that single administration is discouraged and recurrent administration is contraindicated because of HPA-axis suppression risk, adrenal insufficiency, and systemic corticosteroid side effects. Current best practice for allergic rhinitis involves intranasal corticosteroids, antihistamines, and — for disease modification — allergen immunotherapy.
What happens if I drop out of allergy shots early?
Real-world data from Tkacz JP et al., Curr Med Res Opin 2021;37(6):957–965 found that 23.9% of 103,207 allergy immunotherapy patients never returned after the first injection and only 43.9% reached maintenance. Patients who discontinue SCIT before completing 2–3 years of maintenance typically experience symptom recurrence within 12–18 months of stopping, because the underlying allergen sensitivity has not been fully modified. Early discontinuation forfeits the durable remission documented by Durham 1999 NEJM. If the weekly visit burden is the barrier, the discussion should be about schedule alternatives (cluster, rush) or home-based SLIT before starting — not after dropping out.
Related Articles
Allergy Shot Name: SCIT Defined & Explained | Curex
The clinical name for an allergy shot is subcutaneous immunotherapy (SCIT). There is no single brand name — each vial is custom-compounded. SLIT tablets have brand names; SCIT does not.
Read moreAllergy Shot Maintenance Schedule: Cox 2011 Guide | Curex
Allergy shot maintenance: every 2–4 weeks for 3–5 years at ~0.5 mL. 30-min observation continues. Missed-dose rules, Durham 1999 durability, and 42–130 lifetime visit math.
Read moreYearly Allergy Shot: Kenalog vs. SCIT Explained | Curex
A 'yearly allergy shot' is either a depot steroid (Kenalog/Depo-Medrol — AAAAI discourages it) or pre-seasonal SCIT (rare US practice). Neither is disease modification over 3–5 years.
Read moreMonthly Allergy Shots: Maintenance Schedule Guide | Curex
SCIT maintenance shots — every 2-4 weeks for 3-5 years after build-up. Durham 1999 NEJM: 3 years yields 4 years of remission. Missed-dose rules inside.
Read moreAllergy Injection Name: SCIT Defined | Curex
The clinical name for an allergy injection is SCIT (subcutaneous immunotherapy). It has no brand name. Biologics, depot steroids, and epinephrine devices are branded — SCIT is not.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.